Development of therapeutic strategies targeting epigenetics in cancer stem cells
| Project/Area Number |
23592523
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Gunma University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 癌 / 癌幹細胞 / ヒストン脱アセチル化酵素阻害剤 / 頭頸部扁平上皮癌 / 頭頸部癌 |
|---|
| Research Abstract |
Evidence has accumulated indicating that cancer stem cells (CSCs) are responsible for the treatment resistance. Therefore, the development of novel therapeutic strategies to overcome treatment resistance of CSCs is needed. To explore the possibility of targeting epigenetics changes for treatment against CSCs, the effects of two histone deacetylase inhibitors (HDACi), suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA), on CD44+ cancer stem-like cell lines were investigated. The expression of CSC markers was decreased by HDACi treatment. In addition, HDACi decreased mRNA expression levels of stemness-related genes and suppressed the epithelial-mesencymal transition phenotype of CSCs. The combination of HDACi and chemotherapeutic agents had a synergistic effects on tumor cell lines.
|
Report
(4 results)
Research Products
(43 results)
